Xeris Biopharma (NASDAQ:XERS) versus Urogen Pharma (NASDAQ:URGN) Financial Analysis

Urogen Pharma (NASDAQ:URGN – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Urogen Pharma and Xeris Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Urogen Pharma -26.27% N/A -26.88%
Xeris Biopharma -1.76% 147.75% 6.03%

Risk and Volatility

Urogen Pharma has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Urogen Pharma and Xeris Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Urogen Pharma 1 1 8 0 2.70
Xeris Biopharma 1 1 4 0 2.50

Urogen Pharma presently has a consensus target price of $53.38, suggesting a potential upside of 66.91%. Xeris Biopharma has a consensus target price of $17.00, suggesting a potential upside of 3.03%. Given Urogen Pharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Urogen Pharma is more favorable than Xeris Biopharma.

Earnings and Valuation

This table compares Urogen Pharma and Xeris Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Urogen Pharma $109.79 million 14.29 -$153.49 million ($1.32) -24.23
Xeris Biopharma $291.85 million 10.33 $550,000.00 ($0.05) -330.00

Xeris Biopharma has higher revenue and earnings than Urogen Pharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 42.7% of Xeris Biopharma shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 4.3% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Urogen Pharma beats Xeris Biopharma on 8 of the 14 factors compared between the two stocks.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.